Abstract: Provided are a method for diagnosing cancer, a diagnosis kit and compositions useful for measurement of NK cell activity. The incidence of cancer may be diagnosed by monitoring changes in the in vivo immune system through measurement of NK cell activity in blood. Thus, the incidence of cancer may be readily predicted as described herein using a blood sample from a subject.

Abstract: Provided are a method for diagnosing cancer, a diagnosis kit and compositions useful for measurement of NK cell activity. The incidence of cancer may be diagnosed by monitoring changes in the in vivo immune system through measurement of NK cell activity in blood. Thus, the incidence of cancer may be readily predicted as described herein using a blood sample from a subject.

Abstract: The present invention relates to an antibody that recognizes a specific motif of WLS protein so as to inhibit overactivation of the Wnt signaling pathway to thereby prevent or treat a disease associated with the Wnt signaling pathway, and to a pharmaceutical composition containing the same.

Abstract: Provided are a method for diagnosing cancer, a diagnosis kit and compositions useful for measurement of NK cell activity. The incidence of cancer may be diagnosed by monitoring changes in the in vivo immune system through measurement of NK cell activity in blood. Thus, the incidence of cancer may be readily predicted as described herein using a blood sample from a subject.

Abstract: The present invention relates to water soluble magnetic nanocomposite using an amphiphilic compound. Specifically, the present invention relates to water soluble magnetic nanocomposite which may be not only used as a contrast agent for magnetic resonance imaging (MRI), an intelligent contrast agent for diagnosing cancer characterized by binding a tissue-specific binder ingredient, a drug delivery system for simultaneous diagnosis and treatment by polymerizing or enveloping drugs and binding a tissue-specific binder ingredient, but also used for separating a target substance using magnetism, and a process for preparing the same.

Abstract: The present invention provides a humanised form of the antibody 340 obtainable from the cell line deposited with the ECACC under accession number 97021428. Such antibodies have been found to have an increased ability to kill cells compared to the murine antibody 340. Also provided are nucleic acids encoding such antibodies, as well as the use of the antibodies in medicine, in particular in the treatment of cancer.

Abstract: The present invention relates to peptides comprising at least one sequence selected from the group consisting of oligopeptide sequences of at least about 10 but not more than about 50 continuous amino acid residues in the amino acid sequence of the C-terminal acidic tail (ATS), which can render fusion partner proteins environmental stress resistant by binding thereto while conserving their intrinsic properties. Also, it relates to fusion proteins formed by binding the above peptides to fusion partner proteins, nucleotide sequences encoding said fusion proteins, recombinant vectors comprising said nucleotide sequences, and cells transformed or transfected with said recombinant vectors. In addition, it relates to processes for producing the above environmental stress resistance conferring peptides or environmental stress resistant fusion proteins by chemical synthesis or genetic recombination.

Abstract: The present invention relates to a peptide capable of conferring resistance to environmental stresses, comprising a peptide fragment containing a sequence composed of 10 or more consecutive amino acid residues including five or more acidic amino acid residues, wherein the peptide fragment is derived from the C-terminal acidic tail of synuclein, or its derivative, and to a fusion protein comprising the peptide and a fusion partner protein being linked to the peptide, wherein the fusion protein is resistant to environmental stresses. Also, the present invention is concerned with a method of conferring resistance to environmental stress to a protein of interest, comprising linking the protein to the peptide. While maintaining the intrinsic properties of the fusion partner protein, the fusion protein is resistant to environmental stresses, including heat, pH, metal ions, repeated freezing/thawing and high-concentration of polypeptide.

Abstract: The present invention relates to peptides comprising at least one sequence selected from the group consisting of oligopeptide sequences of at least about 10 but not more than about 50 continuous amino acid residues in the amino acid sequence of the C-terminal acidic tail (ATS), which can render fusion partner proteins environmental stress resistant by binding thereto while conserving their intrinsic properties. Also, it relates to fusion proteins formed by binding the above peptides to fusion partner proteins, nucleotide sequences encoding said fusion proteins, recombinant vectors comprising said nucleotide sequences, and cells transformed or transfected with said recombinant vectors. In addition, it relates to processes for producing the above environmental stress resistance conferring peptides or environmental stress resistant fusion proteins by chemical synthesis or genetic recombination.

Abstract: The present invention relates to peptides comprising at least one sequence selected from the group consisting of oligopeptide sequences of at least about 10 but not more than about 50 continuous amino acid residues in the amino acid sequence of the C-terminal acidic tail (ATS), which can render fusion partner proteins environmental stress resistant by binding thereto while conserving their intrinsic properties. Also, it relates to fusion proteins formed by binding the above peptides to fusion partner proteins, nucleotide sequences encoding said fusion proteins, recombinant vectors comprising said nucleotide sequences, and cells transformed or transfected with said recombinant vectors. In addition, it relates to processes for producing the above environmental stress resistance conferring peptides or environmental stress resistant fusion proteins by chemical synthesis or genetic recombination.